Long-term Improvement of Fasting Glycaemia after Switching Basal Insulin from NPH to Determir in Children with Type 1 Diabetes: A 1-Year Multicentre Study
Authors:
Z. Šumník 1; J. Venháčová 2; L. Brázdová 3; J. Škvor 4
Authors place of work:
Pediatrická klinika 2. LF UK a FNM, Praha
1; Dětská klinika LF UP a FN, Olomouc
2; Diabetologická ambulance, Nemocnice Milosrdných bratří, Brno
3; Dětská klinika Masarykovy nemocnice, Ústí nad Labem
4
Published in the journal:
Čas. Lék. čes. 2008; 147: 421-425
Category:
Original Article
Summary
Background.
Paper presents an evaluation of diabetes control after switching from NPH insulin to detemir in children with type 1 diabetes.
Methods and Results.
We performed a non-randomized, observational, multicentre study on the first group of children whose treatment switched from NPH to insulin detemir in four centers of paediatric diabetes. A total of 72 children (39 boys and 33 girls) were included in the analysis. The average age at intervention was 10.6 ± 4.7 yrs, the average age at diabetes onset was 6.2 ± 4.3 yrs. Diabetes control was assessed 3 months prior to the switch and subsequently during 3-month intervals.
Results:
Mean HbA1c decreased from 6.9% at baseline to 6.4% after 3 months of detemir therapy (p = 0.0003). However, in the next months we observed a trend for increasing the HbA1c, and no statistically significant difference in HbA1c was observed at the 6, 9 and 12 months visits vs. baseline. Fasting glycaemia decreased significantly after 3 months of treatment with detemir in comparison with the baseline (the mean value of the difference was 2.1 mmol/l, CI 95% 1.5–2.6, p = 1.4*10-10), and this effect was detectable during all the observational period (month 12 vs. baseline 2.6 mmol/l, p < 10-8).
Conclusions.
Switching basal insulin from NPH insulin to detemir resulted in a short-term improvement of HbA1c, and a long-term decreasing of fasting glycaemia.
Key words:
type 1 diabetes, insulin analogues, detemir, NPH insulin, children.
Zdroje
1. The DCCT research group: Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J. Pediatr., 1994, 125, s. 177–188.
2. Danne, T., Mortensen, H. B., Ougaard, P. et al.: Persistent differences among centers over 3 years in glycemic control and hypoglycemia in a study of 3,805 children and adolescents with type 1 diabetes from the Hvidore Study Group. Diabetes Care, 2001, 24, s. 1342–1347.
3. Cinek, O., Šumník, Z., Vavřinec, J.: Dětský diabetes mellitus v České republice: stále více a čím dál dříve. Čas. Lék. čes., 2005, 144, s. 266–271.
4. Kurtzhals, P.: Pharmacology of insulin detemir. Endocrinol. Metab. Clin. North. Am., 2007, 36 (Suppl. 1), s. 14–20.
5. Chapman, T. M., Perry, C. M.: Insulin Detemir. A Review of its use in the management of type 1 and 2 diabetes mellitus. Drugs, 2004, 64, s. 2577–2595.
6. Holleman, F., Gale, E. A.: Nice insulins, pity about the evidence. Diabetologia, 2007, 50, s. 1783–1790.
7. Robertson, K. J., Schoenle, E., Gucev, Z. et al.: Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet. Med., 2007, 24, s. 27–34.
8. Haladová, I., Lacigová, S., Jankovec, Z. et al.: Klinické zkušenosti s léčbou dlouhodobým inzulinovým analogem glargin v diabetologickém centru. Vnitř. Lék., 2007, 53, s. 632–636.
9. Gough, S. C.: A review of human and analogue insulin trials. Diabetes Res. Clin. Pract., 2007, 77, s. 1–15.
10. Heise, T., Nosek, L., RŅnn, B. B., et al.: Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes, 2004, 53, s. 1614–1620.
11. Vague, P., Selam, J. L., Skeie, S. et al.: Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care, 2003, 26, s. 590–596.
12. Danne, T., Lüpke, K., Walte, K. et al.: Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care, 2003, 26, s. 3087–3092.
13. Home, P., Bartley, P., Russell-Jones, D. et al.: Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care, 2004, 27, s. 1081–1087.
14. Pieber, T. R., Draeger, E., Kristensen, A. et al.: Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet. Med., 2005, 22, s. 850–857.
15. Standl, E., Lang, H., Roberts, A.: The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol. Ther., 2004, 6, s. 579–588.
16. Doyle, E. A., Weinzimer, S. A., Steffen, A. T. et al.: A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care, 2004, 27, s. 1554–1558.
17. Braunholtz, D. A., Edwards, S. J., Lilford, R. J.: Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect”. J. Clin. Epidemiol., 2001, 54, s. 217–224.
18. Martin, D. D., Davis, E. A., Jones, T. W.: Acute effects of hyperglycaemia in children with type 1 diabetes mellitus: the patient’s perspective. J. Pediatr. Endocrinol. Metab., 2006, 19, s. 927–936.
19. Reinehr, T., Holl, R. W., Roth, C. L. et al.: Insulin resistance in children and adolescents with type 1 diabetes mellitus: relation to obesity. Pediatr. Diabetes, 2005, 6, s. 5–12.
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Congenital Deficiency of FVII and Acquired Idiopathic Thrombocytopenic Purpura – the Rare Combination of Two Bleeding Disorders
- Analytical Methods at the Boundary between Biochemistry and Immunology
- Medical Doctors and Nurses – a Dialogue about their Professional Roles and Competences
- Long-term Improvement of Fasting Glycaemia after Switching Basal Insulin from NPH to Determir in Children with Type 1 Diabetes: A 1-Year Multicentre Study